top of page

Poster: SITC 2022 – 37th annual SITC meeting – Nov 8-12 2022, Boston, MA

Poster

April 19, 2022

ACTM-838, a Microbial-based Immunotherapy That Enriches in Solid Tumors After IV Dosing, Reverses the Immunosuppressive TME to Promote Durable Anti-tumor Immunity, Alone and in Combination with Anti-PD1 in Mice

bottom of page